Summary
This umbrella review by Xu et al. (2025) consolidates evidence from existing systematic reviews and meta-analyses of randomised clinical trials to assess the therapeutic potential of curcumin supplementation across multiple chronic disease domains. By aggregating higher-order evidence, the review provides a broad appraisal of effect consistency, magnitude, and methodological quality across the curcumin literature. The work is likely to highlight heterogeneity in study populations, formulations, and bioavailability challenges that limit definitive clinical conclusions.
UK applicability
Although the review is international in scope, its findings are broadly applicable to UK clinical and public health contexts, particularly given growing consumer interest in turmeric and curcumin supplements and ongoing UK dietary guidance discussions around anti-inflammatory nutrition. Clinicians and dietitians in the UK should note that bioavailability limitations and formulation variability identified in such reviews remain relevant when advising patients.
Key measures
Inflammatory biomarkers (e.g. CRP, IL-6); metabolic markers (e.g. fasting glucose, lipid profiles); disease-specific clinical endpoints; adverse event rates; effect sizes from constituent meta-analyses
Outcomes reported
The review synthesises evidence from multiple systematic reviews and meta-analyses of RCTs examining curcumin's effects across a range of chronic disease conditions, reporting on biomarkers, clinical endpoints, and safety outcomes. Key findings likely cover inflammatory markers, metabolic parameters, and disease-specific outcomes across conditions such as cardiovascular disease, type 2 diabetes, and inflammatory disorders.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.